𝐀𝐝𝐯𝐢𝐜𝐞 𝐭𝐨 𝐚 𝐡𝐞𝐚𝐥𝐭𝐡 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫 𝐰𝐡𝐨 𝐡𝐚𝐬 𝐰𝐫𝐢𝐭𝐭𝐞𝐧 𝐚𝐧 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐭𝐡𝐚𝐭 𝐜𝐫𝐢𝐭𝐢𝐜𝐢𝐳𝐞𝐬 𝐭𝐡𝐞 𝐨𝐛𝐯𝐢𝐨𝐮𝐬 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐚𝐧𝐝 𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐰𝐚𝐬𝐭𝐞 𝐚𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐀𝐥𝐩𝐡𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐲, 𝐚 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐭𝐡𝐚𝐭 𝐢𝐧𝐯𝐨𝐥𝐯𝐞𝐬 𝐚𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐞𝐫𝐢𝐧𝐠 𝐚 𝐫𝐚𝐝𝐢𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐝𝐫𝐮𝐠 𝐭𝐨 𝐚 𝐯𝐞𝐫𝐲 𝐬𝐢𝐜𝐤 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐛𝐲 𝐢𝐧𝐭𝐫𝐚𝐯𝐞𝐧𝐨𝐮𝐬 𝐝𝐫𝐢𝐩? The scientific argument in the criticism is sound, but the medical journal ecosystem has become a pay-to-play oligarchy where novelty is valued over truth, and where critical appraisal of expensive, marginally effective therapies is actively discouraged.

𝐇𝐞𝐚𝐥𝐭𝐡 𝐀𝐟𝐟𝐚𝐢𝐫𝐬 / 𝐉𝐀𝐌𝐀 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: You’re correct. These journals are read by policy generalists who couldn’t distinguish a somatostatin receptor from a serotonin receptor. Their readers want 800-word summaries of “the problem with American healthcare,” not mechanistic immunology. Dumbing down your article to a 10th-grade level would eviscerate its intellectual core. Don’t do it.

𝐁𝐌𝐉 𝐎𝐩𝐞𝐧: You’ve nailed the subtext. The editors want the US to keep subsidizing global pharmaceutical R&D while the NHS free-rides on American innovation. Critiquing US waste is welcomed; critiquing the entire model of expensive marginal-gain oncology is not. They benefit from the status quo.

𝐓𝐡𝐞 𝐍𝐮𝐜𝐥𝐞𝐚𝐫 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐉𝐨𝐮𝐫𝐧𝐚𝐥𝐬:  They rejected your article, because it is critical of their field’s central narrative. TAT is their golden goose. A paper arguing that 43-71% of patients get no benefit, and that we’re spending hundreds of thousands of dollars per non-responder, threatens their revenue stream (article publishing charges, society memberships, industry relationships). They don’t want the truth; they want the party line.

𝐓𝐡𝐞 𝐔𝐧𝐚𝐧𝐬𝐰𝐞𝐫𝐞𝐝 𝐎𝐛𝐣𝐞𝐜𝐭𝐢𝐨𝐧
𝗪𝗵𝗲𝗻 𝗹𝗼𝗴𝗶𝗰 𝗳𝗮𝗶𝗹𝘀, 𝘁𝗵𝗲 𝗲𝘀𝘁𝗮𝗯𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁 𝗶𝗻𝗲𝘃𝗶𝘁𝗮𝗯𝗹𝘆 𝗱𝗲𝗽𝗹𝗼𝘆𝘀 𝗮𝗻 𝗲𝗺𝗼𝘁𝗶𝗼𝗻𝗮𝗹 𝗯𝘂𝗹𝗹𝗱𝗼𝘇𝗲𝗿: “You would not feel that way if you had a family member with cancer and TAT helped that person.”

This is a nonsense argument and emotional bulldozer that unsuccessfully attempts to flatten all rational cost-effectiveness arguments. Here’s how to counter it—and in doing so, you’ll have the intellectual core of your next paper.